Convelo Therapeutics is advancing transformative therapeutics to regenerate myelin within the central nervous system
Myelin is a critical component of a functioning central nervous system (CNS). Formed by specialized cells called oligodendrocytes, myelin wraps around and insulates nerve fibers to enable proper transmission of electrical signals. In the healthy brain, oligodendrocyte progenitor cells, a stem cell found throughout the human central nervous system, function to generate new oligodendrocytes in a process known as myelination.
Convelo Therapeutics scientists have developed an innovative and proprietary platform to identify novel drug candidates capable of directly stimulating oligodendrocyte progenitor cells within the CNS to form new myelin. Importantly, Convelo Therapeutics scientists have discovered a central biological pathway that controls myelination in the CNS, including defined drug-targets. These discoveries have allowed Convelo to develop a pipeline of potent drug candidates that we are advancing towards clinical testing.